chr13-48463758-T-C
Position:
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM2PP3_StrongPP5_Very_Strong
The NM_000321.3(RB1):c.2134T>C(p.Cys712Arg) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 12/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: not found (cov: 32)
Consequence
RB1
NM_000321.3 missense
NM_000321.3 missense
Scores
15
3
1
Clinical Significance
Conservation
PhyloP100: 7.65
Genes affected
RB1 (HGNC:9884): (RB transcriptional corepressor 1) The protein encoded by this gene is a negative regulator of the cell cycle and was the first tumor suppressor gene found. The encoded protein also stabilizes constitutive heterochromatin to maintain the overall chromatin structure. The active, hypophosphorylated form of the protein binds transcription factor E2F1. Defects in this gene are a cause of childhood cancer retinoblastoma (RB), bladder cancer, and osteogenic sarcoma. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 14 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.97
PP5
Variant 13-48463758-T-C is Pathogenic according to our data. Variant chr13-48463758-T-C is described in ClinVar as [Likely_pathogenic]. Clinvar id is 13092.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
RB1 | NM_000321.3 | c.2134T>C | p.Cys712Arg | missense_variant | 21/27 | ENST00000267163.6 | NP_000312.2 | |
RB1 | NM_001407165.1 | c.2134T>C | p.Cys712Arg | missense_variant | 21/27 | NP_001394094.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
RB1 | ENST00000267163.6 | c.2134T>C | p.Cys712Arg | missense_variant | 21/27 | 1 | NM_000321.3 | ENSP00000267163.4 | ||
RB1 | ENST00000650461.1 | c.2134T>C | p.Cys712Arg | missense_variant | 21/27 | ENSP00000497193.1 | ||||
RB1 | ENST00000643064.1 | c.192+82315T>C | intron_variant | ENSP00000496005.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 genomes
Cov.:
32
GnomAD4 exome Cov.: 28
GnomAD4 exome
Cov.:
28
GnomAD4 genome Cov.: 32
GnomAD4 genome
Cov.:
32
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:5
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Retinoblastoma Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Sep 08, 2022 | This sequence change replaces cysteine, which is neutral and slightly polar, with arginine, which is basic and polar, at codon 712 of the RB1 protein (p.Cys712Arg). For these reasons, this variant has been classified as Pathogenic. Experimental studies have shown that this missense change affects RB1 function (PMID: 10486322, 18677112). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt RB1 protein function. ClinVar contains an entry for this variant (Variation ID: 13092). This missense change has been observed in individuals with retinoblastoma (PMID: 9671401, 10617920, 10671068, 11668642, 12541220, 16269091, 22084214). It has also been observed to segregate with disease in related individuals. This variant is not present in population databases (gnomAD no frequency). - |
Pathogenic, criteria provided, single submitter | clinical testing | Genetic Diagnostic Laboratory, University of Pennsylvania School of Medicine | May 20, 2024 | Case and Pedigree Information: BILATERAL CASES:1, UNILATERAL CASES:4, TOTAL CASES:5, PEDIGREES:5. ACMG Codes Applied:PM2, PS4M, PP3, PP5 - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Oct 01, 1999 | - - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Mar 09, 2018 | The p.C712R variant (also known as c.2134T>C), located in coding exon 21 of the RB1 gene, results from a T to C substitution at nucleotide position 2134. The cysteine at codon 712 is replaced by arginine, an amino acid with highly dissimilar properties. This alteration has been reported to be associated with a low penetrant phenotype since it has been identified in multiple families with cases of unilateral or regressed tumors and/or unaffected individuals considered at risk for retinoblastoma (Cowell J et al Oncogene. 1998 Jun 18;16(24):3211-3; Valverde J et al BMC Genet. 2005 Nov 4;6:53; Richter S et al Am J Hum Genet. 2003 Feb;72(2):253-69). This variant is located in the A/B pocket and intervening spacer region of the RB1 protein, a critical region of RB1 (Richter S et al Am J Hum Genet. 2003 Feb;72(2):253-69). While alterations to a critical region of the gene are often deleterious, the temperature-sensitive pocket activity of the RB1 gene may explain the observed low penetrance of the C712R alteration (Valverde J et al BMC Genet. 2005 Nov 4;6:53). This amino acid position is highly conserved in available vertebrate species. This splice prediction software does not predict a deleterious effect on splicing. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. - |
Hereditary retinoblastoma Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Genetics and Molecular Pathology, SA Pathology | Nov 21, 2019 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Pathogenic
D;.
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
D;D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D
MetaSVM
Pathogenic
D
MutationAssessor
Pathogenic
M;.
PrimateAI
Pathogenic
D
PROVEAN
Pathogenic
D;.
REVEL
Pathogenic
Sift
Uncertain
D;.
Sift4G
Pathogenic
D;.
Polyphen
D;.
Vest4
MutPred
Gain of catalytic residue at S707 (P = 0);Gain of catalytic residue at S707 (P = 0);
MVP
MPC
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at